GNRSU stock drops to $0.000001 on 06 Apr 2026: low liquidity raises risk

GNRSU stock plunged to $0.000001 on 06 Apr 2026 during U.S. PNK market hours, down 99.99933% from the prior close of $0.15. The intraday volume was thin at 145 shares, leaving trades highly sensitive to order flow and news. Investors should expect extreme price swings and low liquidity given the quoted market cap of $13 and just 12,853,627 shares outstanding.

GNRSU stock intraday move and volume

The day’s price action shows GNRSU stock at $0.000001 with a one-day change of -0.149999 and a percent move of -99.99933%. Volume was 145 shares, far below any meaningful average, highlighting execution risk.

Thin trade depth on the PNK exchange in the United States means even small orders push the price. Market makers and retail traders should account for wide spreads and the risk of failed fills.

GNRSU stock news and company context

Greenrose Holding Company Inc. (GNRSU) operates in Healthcare, specifically Drug Manufacturers – Specialty & Generic, and lists on PNK in the United States. The company website reports cultivation and processing of cannabis products and a 2020 IPO date.

No fresh earnings release was available at the time of the drop. For company details visit the investor page Greenrose Holding Company and the market summary on OTC Markets GNRSU.

GNRSU stock financials and ratios

Reported trailing metrics show EPS of 3.10 and a reported P/E extremely low on quoted data. Book value per share is 4.30 while cash per share is 0.56. Working capital is deeply negative at -103,434,000.00 which increases solvency concern.

The company shows a high debt profile versus market cap, with debt-to-equity around 1.57 and enterprise value listed much larger than market cap. These ratios signal valuation distortion driven by the near-zero market price.

GNRSU stock technicals, liquidity and volatility

Technically, GNRSU stock traded between $0.000001 and $0.000001 intraday, with a 52-week high of $0.15 and a 52-week low of $0.000001. Average 50-day and 200-day prices are both $0.15, showing collapse versus historical averages.

Inventory turnover is low at 0.83 and days-of-inventory is very high at 439.24, indicating operational inefficiencies that can affect near-term cash flows and further pressure the thinly traded quote.

Meyka AI grade and GNRSU stock forecast

Meyka AI rates GNRSU with a score out of 100: 67.12 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects $0.02 for GNRSU stock compared with the current price (USD 1e-06). That projection implies a model-based upside of roughly 1,999,900.00% from the quoted price, although forecasts are model-based projections and not guarantees.

GNRSU stock outlook and trading considerations

Analyst coverage is effectively absent, so price discovery relies on micro trades and any company-disclosed events. Reasonable scenario targets: conservative $0.001, base $0.02, and bull $0.05 price targets, each reflecting liquidity and operational risk.

Given the PNK listing in the United States and the tiny quoted market cap, traders should use limit orders, size cautiously, and treat GNRSU stock as high risk with potential for price gaps and trading halts.

Final Thoughts

GNRSU stock’s intraday quote of $0.000001 on 06 Apr 2026 highlights extreme liquidity stress and valuation distortion. The move down 99.99933% from the prior close and thin volume of 145 shares mean short-term trading is risky and not representative of underlying fundamentals. Financial ratios show mixed signals: EPS is 3.10 and book value per share is 4.30, but working capital is deeply negative and debt metrics are elevated relative to the quoted market cap of $13. Meyka AI rates GNRSU with a 67.12 score (Grade B, Suggestion: HOLD) and offers model-based scenarios. Meyka AI’s forecast model projects $0.02, a model projection only and not a trading recommendation. Traders should watch company announcements, any re-listing activity, and sector news in Healthcare and specialty drug manufacturing before adding exposure. For most investors the immediate risk-reward profile favors waiting for clearer signals and improved liquidity.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.